XTL Biopharmaceuticals Ltd. (XTLB) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
XTLB Revenue Growth
XTLB Revenue Analysis (2013–2024)
As of May 8, 2026, XTL Biopharmaceuticals Ltd. (XTLB) generated trailing twelve-month (TTM) revenue of $451,000. The most recent quarter (Q4 2024) recorded $289,000 in revenue, up 78.4% sequentially.
Looking at the longer-term picture, XTLB's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $2.4 million in 2013.
When compared to Healthcare sector peers including NRXP, SIGA (-22.1% YoY), and BFRI (+11.8% YoY). Compare XTLB vs NRXP →
XTLB Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| XTLBCurrent | $451,000 | - | - | -481.6% | |
 NRXP | $1M | - | - | -1324.4% | |
 SIGA | $95M | -22.1% | -5.4% | 25.1% | |
 BFRI | $42M | +11.8% | +17.2% | -27.2% | |
 AEYE | $40M | +14.5% | +14.5% | -7.9% |
XTLB Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $451K | - | $3K | 0.7% | $-2,172,000 | -481.6% |
| 2023 | $0 | - | $0 | - | $-765,000 | - |
| 2022 | $0 | - | $-1,000 | - | $-880,000 | - |
| 2021 | $0 | - | $-1,000 | - | $-1,031,000 | - |
| 2020 | $0 | - | $-1,000 | - | $-948,000 | - |
| 2019 | $0 | - | $0 | - | $-842,000 | - |
| 2018 | $0 | - | $0 | - | $-793,000 | - |
| 2017 | $0 | - | $0 | - | $-1,246,000 | - |
| 2016 | $0 | - | $0 | - | $-2,561,000 | - |
| 2015 | $0 | - | $0 | - | $-3,611,000 | - |
See XTLB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs XTLB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare XTLB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonXTLB — Frequently Asked Questions
Quick answers to the most common questions about buying XTLB stock.
Is XTLB's revenue growth accelerating or slowing?
XTLB TTM revenue: $451000.00. YoY growth: N/A. 5-year CAGR: N/A.
What is XTLB's long-term revenue growth rate?
XTL Biopharmaceuticals Ltd.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is XTLB's revenue distributed by segment?
XTLB reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.